# DarioHealth Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/DarioHealth Corp.). ## Overview DarioHealth Corp. builds digital health and chronic-condition management solutions that combine self-care apps, coaching, analytics, and connected devices for employers, health plans, and pharmaceutical companies. The company grew out of direct-to-consumer digital health and now sells a broader AI-driven platform through B2B and B2B2C channels, with a growing focus on behavioral health, cardiometabolic care, and medication support. ## Products & services • Dario Health chronic condition management platform • Dario Mind behavioral health support • Dario Move musculoskeletal and activity support • GLP-1 and cardiometabolic support programs • Patient engagement, education, and adherence tools • Data analytics for patient journey and outcomes - **Chronic condition management** (40%) — Digital programs for diabetes, hypertension, weight management, and related conditions. - **Behavioral health** (20%) — Mental health and engagement tools sold to health plans, employers, and members. - **Employer and payer solutions** (25%) — Enterprise deployments for self-insured employers, health plans, and benefit administrators. - **Pharmaceutical partnerships** (10%) — Patient education, adherence support, and journey analytics for drug makers. - **Direct-to-consumer digital health** (5%) — Consumer-facing self-care offerings used as an innovation and testing channel. - Dario Health chronic condition management platform - Dario Mind behavioral health support - Dario Move musculoskeletal and activity support - GLP-1 and cardiometabolic support programs - Patient engagement, education, and adherence tools - Data analytics for patient journey and outcomes ## Customers The core buyers are health plans, self-insured employers, benefit administrators, and pharmaceutical companies that want measurable engagement and lower healthcare costs. The company also serves consumers directly in the U.S., but management says the B2B and B2B2C channels now represent most revenue. Recent disclosures highlight traction with large national health plans, major employers, and a dozen global pharmaceutical companies. - **Health plans** (primary) — Buy member-facing digital health and behavioral health programs to improve engagement and outcomes. - **Medium-to-large employers** (primary) — Purchase chronic condition and wellness solutions to reduce claims costs and improve productivity. - **Pharmaceutical companies** (secondary) — Use the platform for patient education, adherence support, and journey analytics. - **Government and public-sector employers** (secondary) — Adopt the platform for employee health programs and cost containment. - **Direct-to-consumer users** (emerging) — Use self-care tools and digital coaching, mainly as a product development and engagement channel. - National and regional health plans buying member engagement programs - Self-insured employers seeking ROI on chronic care and productivity - Pharmaceutical companies needing adherence and patient journey analytics - Medicare and Medicaid populations targeted for behavioral health - Direct-to-consumer users testing new features before B2B rollout ## Geography DarioHealth is headquartered in the United States and generates most of its commercial activity there, including employer, health plan, and consumer deployments. The company also has significant operational exposure to Israel, where some principal executive officers and other operations are located, and it sources some medical devices and hardware components from China. That mix creates both market concentration in the U.S. and supply-chain and geopolitical exposure abroad. - United States is the main commercial market for employers and health plans - Israel is an important operating base for management and operations - China sourcing exposes hardware supply chains to tariff and trade risk - Global pharma partnerships broaden reach beyond the U.S. core market - B2B2C channels depend on national distribution and partner networks ## Strategy Management is pushing the business from a D2C origin toward scaled enterprise distribution through employers, health plans, benefit administrators, and pharma partners. The current strategy emphasizes integrated chronic care, behavioral health, and GLP-1 support, backed by clinical research and AI personalization to improve outcomes and justify ROI. The company is also using partnerships and new client wins to broaden its customer base and reduce dependence on any single account. - **Scale B2B2C distribution** (short-term) — Enterprise and partner channels now drive most revenue and offer larger, repeatable contracts. - **Expand cardiometabolic and GLP-1 support** (medium-term) — Employers and payers want tools that improve outcomes and help manage expensive therapies. - **Broaden customer diversification** (short-term) — Revenue concentration with a major customer creates downside if that relationship weakens. - Expand enterprise sales across employers, health plans, and pharma - Use D2C as a test bed for new features before B2B rollout - Grow GLP-1 and cardiometabolic support offerings - Leverage behavioral health strength in Medicare and Medicaid - Add channel partners such as benefit administrators and consultants - Use clinical research to support adoption and pricing ## Risks The company faces customer concentration risk, since a major customer still represents a meaningful share of revenue and receivables. It also has supply-chain and execution risk from tariff exposure and China-sourced hardware components, plus covenant and financing risk after missing a debt covenant and relying on lender discussions and potential equity cure. As a digital health business, it also depends on continued employer and payer adoption, clinical evidence, and stable reimbursement and procurement behavior. - **Customer concentration** [high] — A major customer still accounts for a meaningful share of revenue and receivables, so loss or underperformance would reduce sales quickly. - **Debt covenant breach** [high] — The company did not meet one financial covenant and may need waivers, amendments, or an equity cure to avoid worse financing terms. - **Tariff and supply-chain disruption** [medium] — Some medical devices and hardware components are manufactured in China, making the business vulnerable to trade policy changes and sourcing delays. - **Geopolitical exposure in Israel** [medium] — Principal executive officers and significant operations are in Israel, so conflict or instability could disrupt operations and execution. - **Nasdaq listing and stock volatility** [medium] — Low share price and extreme volatility can restrict access to capital and increase financing uncertainty. - Revenue concentration could hurt results if a major customer leaves - Debt covenant pressure may limit flexibility and force dilutive financing - Tariffs and China sourcing can delay hardware and raise costs - Israel-based operations add geopolitical and military instability risk - Enterprise sales cycles can be long and implementation can slip - Stock price volatility and Nasdaq compliance issues add capital-market risk ## Accounting Revenue recognition depends on multi-period enterprise contracts, partner implementations, and recurring service delivery, so timing can shift with onboarding and client go-live dates. Investors should also watch acquisition-related accounting from Twill, including amortization, stock-based compensation, and any goodwill or intangible asset impairment risk, because these items materially affect reported margins and losses. The company also uses fair value remeasurement for warrants and other financing-related instruments, which can create large non-operating swings in earnings. - **Revenue recognition timing** — Quarterly revenue comparability - **Acquisition-related intangible amortization** — Reported profitability - **Fair value remeasurement of warrants** — Net income volatility - **Stock-based compensation** — G&A and operating loss - **Debt covenant compliance** — Financing costs and liquidity - Revenue timing can move with client implementation and contract go-live dates - Twill acquisition created amortization and acquisition-related expense noise - Stock-based compensation materially affects G&A and reported losses - Warrant revaluation can swing financial income or expense sharply - Debt accounting and covenant issues may affect interest and liquidity disclosures - Lease and other operating commitments remain relevant for cash flow analysis --- *Last updated: 2026-04-28T20:01:26.620219+00:00*